Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2019

Open Access 01.12.2019 | Research

Association between serum zinc levels and lung cancer: a meta-analysis of observational studies

verfasst von: Ying Wang, Zhengyi Sun, Aipeng Li, Yongsheng Zhang

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2019

Abstract

Background

Inconsistent results according to numerous studies that had investigated the association between serum zinc levels and lung cancer risk were reported. The aim of this study was to explore whether serum zinc levels were lower in lung cancer patients than that in controls.

Methods

We systematically retrieved the databases of PubMed, Wanfang, Cochrane, ScienceDirect website, CNKI, and SinoMed databases for comprehensive relevant studies published before December 2018 and conducted a meta-analysis. Standard mean differences (SMD) were pooled using a random effects model.

Results

Thirty-two articles were eligible to investigate the correlation between serum zinc levels and lung cancer risk, involving 2894 cases and 9419 controls. The pooled results showed sufficient evidence approving the association between serum zinc levels and lung cancer risk. And the serum zinc levels in lung cancer were significantly lower than that in controls (summary SMD = − 0.88, 95% confidence interval (CI) = − 0.94, − 0.82). Meanwhile, consistent results were obtained both in European populations and Asian populations. No publication bias was detected in our analysis.

Conclusions

The present meta-analysis suggested that serum zinc levels were significantly lower in lung cancer patients than that in controls.
Abkürzungen
SMD
Standard mean differences
CI
Confidence interval
SD
Standard deviation

Introduction

Cancer is a crucial health problem on a global scale that has become one of the primary causes of death. The increasing trend in cancer globally could be slowed and reversed if preventive measures could provide the feasible approach [1]. As we all know, smoking had been as the well-known role in the development of lung cancer [2]. Previous studies had confirmed that some external environment exposure [3, 4], dietary factors [5, 6], and physical activities [7] could affect the risk of lung cancer. However, some trace element concentrations, such as zinc, copper, and so on, could also influence the development of lung cancer. A recent meta-analysis had been performed to explore the relationship about serum copper levels in lung cancer [8]. Copper and zinc are closely related trace elements. Zinc is used for the growth of cells and is also useful in maintaining the integrity of the cell membrane. Therefore, cancer cells may consume zinc in the circulation to maintain cancer growth and maintain its membrane integrity [9]. However, there has not been an article attempting to summarize the results for serum zinc levels on the risk of lung cancer. So far, numerous researchers have examined potential effects of serum zinc levels on lung cancer risk, but existing epidemiological data are inconsistent. Hence, we aimed to evaluate results from previous studies systematically and carefully by constructing a meta-analysis of observational studies to find whether serum zinc levels were lower in lung cancer patients than that in controls.

Methods

This meta-analysis was designed and performed according to the guidelines of the preferred reporting items for systematic reviews and meta-analyses (PRISMA compliant) statement [10].

Data sources and searches

A comprehensive, computerized literature search regarding the association between serum zinc levels and lung cancer risk was conducted in six databases (PubMed, Wanfang, Cochrane, ScienceDirect website, CNKI, and SinoMed databases), from their inception to December 2018. Combinations of the following keywords were used for the search: “zinc levels” OR “zinc concentration” OR “zinc” OR “trace element” in combination with “lung cancer” OR “lung tumor”. Moreover, we also scrutinized the references of retrieved publications to identify any studies that were potentially missed.

Study selection criteria

To be eligible for our analysis, the studies had to meet the following criteria: (1) epidemiological studies; (2) the aim was to evaluate the associations between serum zinc levels and lung cancer risk; (3) the numbers, mean, and standard deviation (SD) of serum zinc levels for cases and control are available. It is noted that duplicated results may be published in more than one paper, so we selected the most recent or most informative paper in our analysis.

Data extraction and quality assessment

Two of the authors extracted all data independently, complying with the selection criteria above. A standardized data collection protocol was as follows: the last name of the first author, publication year, study design, the location of the study conducted in, subject in cases and control, gender, range or mean age of cases, method of measurement for serum zinc, and mean and SD of serum zinc levels for cases and control.

Statistical analysis

The strength of the association between serum zinc levels and lung cancer risk was measured by standard mean differences (SMD) and 95% confident interval (CI) by adopting random effects models that taking into account both within-study and between-study variations [11]. The analysis evaluated heterogeneity among researches via the Cochran’s Q test and I2 (inconsistency index) statistic [12]. Subgroup analysis based on study design and geographic location was conducted in this meta-analysis to explore possible heterogeneity and to analyze whether there was a correlation in some subgroups. The meta-regression analysis was also performed to examine the possible heterogeneity [13]. Furthermore, sensitivity analysis was done to estimate the stability of the results by removing each study from the analysis, one at a time, which can evaluate the influence of a single comparison on the overall risk estimate. We also adopted Begg’s funnel plots [14] and Egger’s linear regression test [15] to evaluate whether publication bias existed. All the statistical analyses involved were performed with STATA software. P values were two-sided and less than 0.05 was considered statistically significant.

Results

Literature search and study characteristics

The specific step of searching and selecting relevant articles was summarized in Fig. 1. To sum up, we retrieved 204 articles from PubMed, 231 articles from Wanfang databases, 198 articles from Cochrane, 221 articles from ScienceDirect website, 265 articles from CNKI, and 248 articles from SinoMed databases. Fifty-nine articles were reviewed in full text. By evaluating the full text, 27 articles were further excluded owing to listed reasons below: review articles (n = 13), not reported mean or SD (n = 7), reported dietary factors (n = 5), and letter to the editor (n = 2). Ultimately, 32 articles [1647] met the inclusion criteria. Three studies came from Europe and the remaining 29 studies were from Asia. The characteristics of the included studies are shown in Table 1.
Table 1
Characteristics of studies between serum zinc levels and lung cancer risk
Study, year
Country
Study type
Age
Lung cancer cases
Controls
Methods of measured zinc
n
Zinc: mean ± SD
n
Zinc: mean ± SD
Sun et al., 1991
China
Case-control
30–75
104
M = 0.945 ± 0.303(μg/mL)
F = 0.970 ± 0.229 (μg/mL)
252
M = 0.945 ± 0.23(μg/mL)
F = 1.08 ± 0.197 (μg/mL)
Atomic absorption spectrophotometer measurements (IL-951, USA)
Cobanoglu et al., 2010
Turkey
Case-control
54 ± 8.29
30
0.539 ± 0.225 (μg/dL)
20
2.051 ± 0.298 (μg/dL)
UNICAM-929 spectrophotometer (Unicam Ltd, York Street, Cambridge, UK)
Diez et al., 1989
Spain
Case-control
60 ± 7
64
0.627 ± 0.136 (μg/mL)
100
0.733 ± 0.173 (μg/mL)
Perkin-Elmer 5.000 atomic absorption spectrophotometer
Jin et al., 2011
China
Case-control
34.9 ± 21.3
154
0.673 ± 0.47 (μg/mL)
154
1.27 ± 0.442 (μg/mL)
Atomic absorption spectrophotometer (Wako Pure Chemical Industries, Osaka, Japan)
Oyama et al., 1994
Japan
Case-control
26–83
109
0.853 ± 0.279 (μg/mL)
53
0.873 ± 0.324 (μg/mL)
Atomic absorption spectrophotometry (Wako Pure Chemical Industries, Osaka, Japan)
Zablocka-Slowinska et al., 2018
Poland
Case-control
50–70
44
0.86 ± 0.215 (μg/L)
44
0.99 ± 0.263 (μg/L)
Atomic absorption spectrometry
Zowczak et al., 2001
Poland
Case-control
42–87
14
12 ± 2 (μmol/L)
18
13.8 ± 2 (μmol/L)
Flame atomic absorption spectrometry using Perkin ELmer spectrometer
Feng et al., 2006
China
Observation study
18–82
13
17.72 ± 2.55 (μmol/L)
36
17.57 ± 2.74 (μmol/L)
Flame atomic absorption spectrometry
Zhang et al., 1997
China
Case-control
25–80
64
0.788 ± 0.171 (μg/mL)
31
0.91 ± 0.374 (μg/mL)
Atomic absorption spectrophotometer measurements
Jin et al., 2001
China
Case-control
45–70
40
11.1 ± 3.73 (μmol/L)
46
13.4 ± 2.5 (μmol/L)
Atomic absorption spectrophotometer measurements
Zhang et al., 1994
China
Case-control
59 ± 9
40
16.98 ± 3.06 (μmol/L)
24
20.96 ± 3.67 (μmol/L)
Atomic absorption spectrophotometer measurements
Xu et al., 1993
China
Case-control
56 ± 7.5
42
11.45 ± 2.08 (μmol/L)
40
13.78 ± 2.12 (μmol/L)
Atomic absorption spectrophotometer measurements
Zhou et al., 1995
China
Case-control
39–69
186
0.702 ± 0.182 (μg/mL)
150
0.976 ± 0.102 (μg/mL)
Atomic absorption spectrophotometer measurements
Chen et al., 1994
China
Case-control
37–72
58
27.4 ± 4.8 (mol/L)
100
14.5 ± 3.8 (mol/L)
Atomic absorption spectrophotometer measurements (MFX-ID)
Luo et al., 1996
China
Case-control
40–70
35
10.25 ± 1.38 (μmol/L)
22
12.85 ± 4.28 (μmol/L)
Atomic Absorption Spectrophotometer measurements
Mo et al., 1995
China
Case-control
58.5
57
0.719 ± 0.159 (μg/mL)
46
0.955 ± 0.139 (μg/mL)
Atomic absorption spectrophotometer measurements
He et al., 1995
China
Case-control
34–72
143
19.481 ± 3.671(μmol/L)
50
21.436 ± 6.278(μmol/L)
Atomic absorption spectrophotometer measurements
Wei L et al., 2002
China
Case-control
22–76
79
0.832 ± 0.092 (μg/mL)
32
1.182 ± 0.018 (μg/mL)
Atomic absorption spectrophotometer measurements (American p-100)
Zhao et al., 1993
China
Case-control
43–62
46
11.17 ± 3.74 (μmol/L)
50
16.92 ± 5.6 (μmol/L)
Atomic absorption spectrophotometer measurements (BJKP-36)
He et al., 2011
China
Case-control
38–69
104
9.08 ± 1.44 (μmol/L)
122
16.44 ± 1.69 (μmol/L)
Atomic absorption spectrophotometer measurements
Chen et al., 1998
China
Case-control
47–72
43
11.74 ± 2.74 (μmol/L)
180
13 ± 1.83 (μmol/L)
Atomic absorption spectrophotometer measurements (Japan Shimadzu-A670)
Liang et al., 1992
China
Case-control
61
57
13.86 ± 5.56 (μmol/L)
80
21.81 ± 3.38 (μmol/L)
Atomic absorption spectrophotometer measurements (Chinese WFX-ID)
Huang et al., 1998
China
Case-control
25–65
136
11.933 ± 2.68 (μmol/L)
7101
19.808 ± 6.43(μmol/L)
Atomic absorption spectrophotometer measurements (Japan Shimadzu-AA670/C2H2)
Wang et al., 2003
China
Case-control
28–69
50
0.74 ± 0.18 (μg/L)
60
1.83 ± 1.44 (μg/L)
Atomic absorption spectrophotometer measurements
Cheng et al., 2011
China
Case-control
37–68
197
0.9 ± 0.3 (μmol/L)
93
1.12 ± 0.56 (μmol/L)
Atomic absorption spectrophotometer measurements
Xie et al., 2000
China
Case-control
35–68
64
70.28 ± 10.6 (μmol/L)
100
80.3 ± 20.7 (μmol/L)
Atomic absorption spectrophotometer measurements
Du et al., 1996
China
Case-control
22–73
73
13.1 ± 4 (μmol/L)
63
15.2 ± 3.5 (μmol/L)
Atomic absorption spectrophotometer measurements
Zhu et al., 1997
China
Case-control
NA
56
13.16 ± 1.71 (μmol/L)
118
15.46 ± 2.13 (μmol/L)
Atomic absorption spectrophotometer measurements (Perkin Elmer Zeeman/3030, USA)
Zhang et al., 2000
China
Case-control
25–77
310
0.812 ± 0.16 (μg/mL)
48
1.039 ± 0.154 (μg/mL)
Atomic absorption spectrophotometer measurements (Japan Shimadzu-180-80)
Hu et al., 2000
China
Case-control
36–77
56
0.797 ± 0.176 (μg/mL)
60
0.908 ± 0.022 (μg/mL)
Atomic Absorption Spectrophotometer measurements
Guo et al., 1994
China
Case-control
55.1
26
1.28 ± 0.94 (μg/mL)
26
0.8 ± 0.25 (μg/mL)
Atomic absorption spectrophotometer measurements (Varian Spectr AA-40p, USA)
Han et al., 1999
China
Case-control
4–77
400
0.93 ± 0.38 (μg/mL)
100
1.1 ± 0.36 (μg/mL)
Atomic absorption spectrophotometer measurements (American PE3030)
SD standard deviation, NA not available, F female, M male

Serum zinc levels and lung cancer risk

In each study included in our analysis, 27 studies suggested that serum zinc levels were lower in lung cancer patients than that in controls, while four studies found a non-significant association between serum zinc levels and lung cancer. However, two studies obtained a positive association between serum zinc levels and lung cancer. Figure 2 has demonstrated the investigation results of the association between serum zinc levels and lung cancer in all the articles, as serum zinc levels in lung cancer were significantly lower than controls (summary SMD = − 0.88, 95% CI = − 0.94, − 0.82, Z value = 28.32, P for Z test < 0.001). Extreme heterogeneity was present among the pooled results (P < 0.001, I2 = 96.5%). Based on Egger’s test (P = 0.548) and the Begg’s funnel plot (Fig. 3), there existed no publication bias.

Stratified analysis

Subgroup analyses by study design and geographic location were conducted to further examine serum zinc levels and lung cancer risk. We found lower serum zinc levels in lung cancer patients than that in controls both in European populations (summary SMD = − 0.65, 95% CI = − 0.89, − 0.41, Z value = 5.25, P for Z test < 0.001, I2 = 0.0%) and Asian populations (summary SMD = − 0.90, 95% CI = − 0.96, − 0.83, Z value = 27.90, P for Z test < 0.001, I2 = 96.8%). Thirty-one of the 32 studies were case-control studies, and the result was consistent with the overall result (summary SMD = − 0.89, 95%CI = − 0.95, − 0.83, Z value = 28.47, P for Z test < 0.001, I2 = 96.6%).

Meta-regression analysis

Meta-regression analysis was evaluated in this article, indicating that no source of heterogeneity was observed in the association between serum zinc levels and lung cancer risk.

Sensitivity analysis

Sensitivity analysis indicated that no evidence of overall result changing was observed when removed each study from the analysis, one at a time.

Discussion

The meta-analysis was conducted to investigate the association between serum zinc levels and lung cancer. Findings from our report suggested that serum zinc levels in lung cancer cases were significantly lower than that in controls. Consistent results were found both in European populations and Asian populations.
Some previous studies had been published to explore serum element levels and lung cancer risk. Chen et al. performed a meta-analysis with 13 publications to assess the association between serum iron levels and lung cancer risk [48]. The authors concluded that serum iron levels had no effect on the risk of lung cancer. Song et al. found no significant association between serum magnesium levels and lung cancer risk when pooled 11 suitable papers [49]. However, Zhang et al. performed a meta-analysis using 33 articles to explore the association between serum copper levels and the risk of lung cancer [8]. Results from their study suggested that serum copper levels were higher in lung cancer than that in controls. Copper and zinc are closely related trace elements involved in cell proliferation, growth, gene expression, apoptosis, and other processes. These two trace elements are all necessary for the proper activity of superoxide dismutase due to their integral role as cofactors or ions stabilizing the molecular structure [50]. Zinc deficiency may have adverse events, especially on immune function [51]. Gómez et al. had studied the association of zinc and its role in lung cancer [52]. In general, zinc microenvironment may play a key role in oxidative stress, apoptosis, and/or cell signaling alterations which influence the behavior of malignant cancer cells [52], and this may play a role in preventing lung cancer.
Previous studies had significantly revealed that serum zinc had a protective effect on some cancers. Xie et al. conducted a meta-analysis about serum zinc levels and cervical cancer, indicating that serum zinc levels were lower in cervical cancer patients than controls [53]. In addition, Mao et al. found that bladder cancer patients had lower serum zinc levels compared with controls [54]. Moreover, a meta-analysis published by Zhao et al. suggested that serum zinc concentrations in prostate cancer patients were significantly lower than those in normal controls [55]. Our results were consistent with the abovementioned studies.
However, there are some limitations and potential bias that must be acknowledged in our meta-analysis. First, we only included papers published in English or Chinese, which may omit some other language paper. Furthermore, we only searched published articles, which may omit some unpublished articles or some meeting articles. These factors may yield between-study heterogeneity and publications bias in the overall pooled results. Second, although most method of measurement for serum zinc was using atomic absorption spectrophotometer, different methods of measurement as well as a different instrument could also cause between-study heterogeneity. Third, evidence of high heterogeneity was found, both in overall and subgroup analysis, in our analysis. However, we could not find the source of heterogeneity due to stratified analysis and meta->regression analysis concerning the relationship between serum zinc levels and lung cancer risk. Fourth, our meta-analysis included three articles from Europe and 29 articles from Asia, thus, further epidemiological studies are warranted in the future to assess the association between serum zinc levels and lung cancer risk.

Conclusions

In summary, our meta-analysis, which included a large number of subjects of 32 articles, manifested that serum zinc levels were significantly lower in lung cancer patients than that in controls.

Acknowledgements

None

Funding

None

Availability of data and materials

The tables and figures supporting the conclusions of this article are included within the article.
Not applicable
Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Thun MJ, JO DL, Center MM, et al. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–10.PubMedCrossRef Thun MJ, JO DL, Center MM, et al. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–10.PubMedCrossRef
2.
Zurück zum Zitat O'Keeffe LM, Taylor G, Huxley RR, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10):e021611.PubMedPubMedCentralCrossRef O'Keeffe LM, Taylor G, Huxley RR, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10):e021611.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Jia PL, Zhang C, Yu JJ, et al. The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies. J Cancer Res Clin Oncol. 2018;144(2):229–40.PubMedCrossRef Jia PL, Zhang C, Yu JJ, et al. The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies. J Cancer Res Clin Oncol. 2018;144(2):229–40.PubMedCrossRef
4.
Zurück zum Zitat Mundt KA, Dell LD, Crawford L, et al. Cancer risk associated with exposure to bitumen and bitumen fumes: an updated systematic review and meta-analysis. J Occup Environ Med. 2018;60(1):e6–e54.PubMedCrossRef Mundt KA, Dell LD, Crawford L, et al. Cancer risk associated with exposure to bitumen and bitumen fumes: an updated systematic review and meta-analysis. J Occup Environ Med. 2018;60(1):e6–e54.PubMedCrossRef
5.
Zurück zum Zitat Chen G, Wang J, Hong X, et al. Dietary vitamin E intake could reduce the risk of lung cancer: evidence from a meta-analysis. Int J Clin Exp Med. 2015;8(4):6631–7.PubMedPubMedCentral Chen G, Wang J, Hong X, et al. Dietary vitamin E intake could reduce the risk of lung cancer: evidence from a meta-analysis. Int J Clin Exp Med. 2015;8(4):6631–7.PubMedPubMedCentral
6.
7.
Zurück zum Zitat Zhong S, Ma T, Chen L, et al. Physical activity and risk of lung cancer: a meta-analysis. Clin J Sport Med. 2016;26(3):173–81.PubMedCrossRef Zhong S, Ma T, Chen L, et al. Physical activity and risk of lung cancer: a meta-analysis. Clin J Sport Med. 2016;26(3):173–81.PubMedCrossRef
9.
Zurück zum Zitat Schwartz MK. Role of trace elements in cancer. Cancer Res. 1975;35(11 Pt. 2):3481–7.PubMed Schwartz MK. Role of trace elements in cancer. Cancer Res. 1975;35(11 Pt. 2):3481–7.PubMed
10.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedPubMedCentralCrossRef Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef
13.
Zurück zum Zitat Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23(11):1663–82.PubMedCrossRef Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23(11):1663–82.PubMedCrossRef
14.
Zurück zum Zitat Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef
15.
16.
Zurück zum Zitat Sun ZP, Meng SX, Xu PY, et al. Study on serum copper and zinc levels and copper/zinc ratio in 102 lung cancer patients. Trace Elem Health Res. 1991;1:67–9. Sun ZP, Meng SX, Xu PY, et al. Study on serum copper and zinc levels and copper/zinc ratio in 102 lung cancer patients. Trace Elem Health Res. 1991;1:67–9.
17.
Zurück zum Zitat Cobanoglu U, Demir H, Sayir F, et al. Some mineral, trace element and heavy metal concentrations in lung cancer. Asian Pac J Cancer Prev. 2010;11(5):1383–8.PubMed Cobanoglu U, Demir H, Sayir F, et al. Some mineral, trace element and heavy metal concentrations in lung cancer. Asian Pac J Cancer Prev. 2010;11(5):1383–8.PubMed
18.
Zurück zum Zitat Diez M, Arroyo M, Cerdan FJ, et al. Serum and tissue trace metal levels in lung cancer. Oncology. 1989;46(4):230–4.PubMedCrossRef Diez M, Arroyo M, Cerdan FJ, et al. Serum and tissue trace metal levels in lung cancer. Oncology. 1989;46(4):230–4.PubMedCrossRef
19.
Zurück zum Zitat Jin Y, Zhang C, Xu H, et al. Combined effects of serum trace metals and polymorphisms of CYP1A1 or GSTM1 on non-small cell lung cancer: a hospital based case-control study in China. Cancer Epidemiol. 2011;35(2):182–7.PubMedCrossRef Jin Y, Zhang C, Xu H, et al. Combined effects of serum trace metals and polymorphisms of CYP1A1 or GSTM1 on non-small cell lung cancer: a hospital based case-control study in China. Cancer Epidemiol. 2011;35(2):182–7.PubMedCrossRef
20.
Zurück zum Zitat Oyama T, Matsuno K, Kawamoto T, et al. Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biol Trace Elem Res. 1994;42(2):115–27.PubMedCrossRef Oyama T, Matsuno K, Kawamoto T, et al. Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biol Trace Elem Res. 1994;42(2):115–27.PubMedCrossRef
21.
Zurück zum Zitat Zablocka-Slowinska K, Placzkowska S, Prescha A, et al. Serum and whole blood Zn, Cu and Mn profiles and their relation to redox status in lung cancer patients. J Trace Elem Med Biol. 2018;45:78–84.PubMedCrossRef Zablocka-Slowinska K, Placzkowska S, Prescha A, et al. Serum and whole blood Zn, Cu and Mn profiles and their relation to redox status in lung cancer patients. J Trace Elem Med Biol. 2018;45:78–84.PubMedCrossRef
22.
Zurück zum Zitat Zowczak M, Iskra M, Paszkowski J, et al. Oxidase activity of ceruloplasmin and concentrations of copper and zinc in serum of cancer patients. J Trace Elem Med Biol. 2001;15(2-3):193–6.PubMedCrossRef Zowczak M, Iskra M, Paszkowski J, et al. Oxidase activity of ceruloplasmin and concentrations of copper and zinc in serum of cancer patients. J Trace Elem Med Biol. 2001;15(2-3):193–6.PubMedCrossRef
23.
Zurück zum Zitat Feng JF, Li SL. Correlation between oxidative stress and trace elements in blood of patients with cancer. Chin J of Clinic Reh. 2006;10(4):187–90. Feng JF, Li SL. Correlation between oxidative stress and trace elements in blood of patients with cancer. Chin J of Clinic Reh. 2006;10(4):187–90.
24.
Zurück zum Zitat Zhang Y. Clinical significance of determination of serum lead, zinc and copper to zinc ratio in patients with lung cancer. Trace Elem Sci Guangdong. 1997;4(3):32–4. Zhang Y. Clinical significance of determination of serum lead, zinc and copper to zinc ratio in patients with lung cancer. Trace Elem Sci Guangdong. 1997;4(3):32–4.
25.
Zurück zum Zitat Jin ZJ, Qian LQ, Dong GQ, et al. Measurement and analysis of serum copper, zinc and magnesium in patients with lung cancer and gastric cancer. Shaanxi Med J. 2001;30(3):165–6. Jin ZJ, Qian LQ, Dong GQ, et al. Measurement and analysis of serum copper, zinc and magnesium in patients with lung cancer and gastric cancer. Shaanxi Med J. 2001;30(3):165–6.
26.
Zurück zum Zitat Zhang TQ, Yao RL, Song MC. Copper, zinc and copper-zinc ratio in plasma of patients with lung cancer. Shaanxi Med J. 1994;25(4):349–51. Zhang TQ, Yao RL, Song MC. Copper, zinc and copper-zinc ratio in plasma of patients with lung cancer. Shaanxi Med J. 1994;25(4):349–51.
27.
Zurück zum Zitat Xu ZF, Sun YC, Zhang CW, et al. Clinical significance of changes of serum copper, zinc and magnesium contents in patients with lung cancer. J Second Mil Med Univ. 1993;14(2):195–6. Xu ZF, Sun YC, Zhang CW, et al. Clinical significance of changes of serum copper, zinc and magnesium contents in patients with lung cancer. J Second Mil Med Univ. 1993;14(2):195–6.
28.
Zurück zum Zitat Zhou QH, Luo YY, Li CF, et al. A study on serum copper and zinc levels in patients with lung cancer. Chinese J Clin Thorac Cardiovasc Surg. 1995;2(1):45–7. Zhou QH, Luo YY, Li CF, et al. A study on serum copper and zinc levels in patients with lung cancer. Chinese J Clin Thorac Cardiovasc Surg. 1995;2(1):45–7.
29.
Zurück zum Zitat Chen ZH, Chen NJ, Chen LJ, et al. Detection of serum copper, zinc and iron in patients with lung cancer and lung infection and its clinical significance. J Guangzhou Med Coll. 1994;12(2):118–9. Chen ZH, Chen NJ, Chen LJ, et al. Detection of serum copper, zinc and iron in patients with lung cancer and lung infection and its clinical significance. J Guangzhou Med Coll. 1994;12(2):118–9.
30.
Zurück zum Zitat Luo XR, Mao WG. Changes of serum copper and zinc in patients with lung cancer and its clinical significance. Hunan Med. 1996;13(3):136–7. Luo XR, Mao WG. Changes of serum copper and zinc in patients with lung cancer and its clinical significance. Hunan Med. 1996;13(3):136–7.
31.
Zurück zum Zitat Mo LN, Du KX, Liu GC. Analysis of serum CEA and trace elements Zn and Cu in patients with lung cancer. Radioimmunology. 1995;8(6):354–5. Mo LN, Du KX, Liu GC. Analysis of serum CEA and trace elements Zn and Cu in patients with lung cancer. Radioimmunology. 1995;8(6):354–5.
32.
Zurück zum Zitat He WD. Detection and analysis of some trace elements in serum of patients with lung cancer. Jiujiang Med J. 1995;10(2):69–71. He WD. Detection and analysis of some trace elements in serum of patients with lung cancer. Jiujiang Med J. 1995;10(2):69–71.
33.
Zurück zum Zitat Wei L, Ji QM, Xue DY, et al. The role of copper and zinc determination in patients with lung cancer. Chinese Tumor. 2002;11(3):182–3. Wei L, Ji QM, Xue DY, et al. The role of copper and zinc determination in patients with lung cancer. Chinese Tumor. 2002;11(3):182–3.
34.
Zurück zum Zitat Zhao YM, Zhang XP. The value of serum copper and zinc levels and their ratio in diagnosis of lung cancer. Shanghai Med Inspection J. 1993;8(2):120-21. Zhao YM, Zhang XP. The value of serum copper and zinc levels and their ratio in diagnosis of lung cancer. Shanghai Med Inspection J. 1993;8(2):120-21.
35.
Zurück zum Zitat He ZJ. Detection of serum trace elements in lung cancer patients and its significance. Med Innovation of China. 2011;8(18):118–9. He ZJ. Detection of serum trace elements in lung cancer patients and its significance. Med Innovation of China. 2011;8(18):118–9.
36.
Zurück zum Zitat Chen WY. Changes of serum trace elements copper and zinc in patients with lung cancer. Zhejiang Med. 1998;20(6):330–1. Chen WY. Changes of serum trace elements copper and zinc in patients with lung cancer. Zhejiang Med. 1998;20(6):330–1.
37.
Zurück zum Zitat Liang GM, Zhu XH, Wang X. Serum zinc and copper levels and copper/zinc ratios in patients with lung cancer. Cancer Res. 1992;19(3):193–4. Liang GM, Zhu XH, Wang X. Serum zinc and copper levels and copper/zinc ratios in patients with lung cancer. Cancer Res. 1992;19(3):193–4.
38.
Zurück zum Zitat Huang ZY, Hu FD. Comparative study of serum trace elements in patients with lung cancer. Shanxi Clin Med J. 1998;17(2):114–6. Huang ZY, Hu FD. Comparative study of serum trace elements in patients with lung cancer. Shanxi Clin Med J. 1998;17(2):114–6.
39.
Zurück zum Zitat Wang ZL, Zhang W, Zhang HY, et al. Determinat ion of serum trace elements and their clinical value in patients with lung cancer. Clin Focus. 2003;18(4):183–5. Wang ZL, Zhang W, Zhang HY, et al. Determinat ion of serum trace elements and their clinical value in patients with lung cancer. Clin Focus. 2003;18(4):183–5.
40.
Zurück zum Zitat Cheng Z, Dai LL, Kang Y, et al. Detection of trace elements of patients with lung cancers and pulmonary infections and its clinical significance. Chin J Nosocomiol. 2011;21(10):2006–8. Cheng Z, Dai LL, Kang Y, et al. Detection of trace elements of patients with lung cancers and pulmonary infections and its clinical significance. Chin J Nosocomiol. 2011;21(10):2006–8.
41.
Zurück zum Zitat Xie SY, Chen YX. Analysis of 64 cases of lung cancer with trace elements copper and zinc. Shanxi Med J. 2000;29(2):83–4. Xie SY, Chen YX. Analysis of 64 cases of lung cancer with trace elements copper and zinc. Shanxi Med J. 2000;29(2):83–4.
42.
Zurück zum Zitat Du FL, Li ZM, Cao MJ, et al. Determination of serum copper, zinc, magnesium and iron in patients with pulmonary tuberculosis, chronic bronchitis, pulmonary heart disease and lung cancer. J of Xi'an Med Univ. 1996;17(3):348–50. Du FL, Li ZM, Cao MJ, et al. Determination of serum copper, zinc, magnesium and iron in patients with pulmonary tuberculosis, chronic bronchitis, pulmonary heart disease and lung cancer. J of Xi'an Med Univ. 1996;17(3):348–50.
43.
Zurück zum Zitat Zhu JJ, Duan XY, Liu JS. The diagnostic value of serum copper and zinc concentrations in lung cancer, pulmonary tuberculosis and pulmonary infection. China J Modern Med. 1997;7(10):11–3. Zhu JJ, Duan XY, Liu JS. The diagnostic value of serum copper and zinc concentrations in lung cancer, pulmonary tuberculosis and pulmonary infection. China J Modern Med. 1997;7(10):11–3.
44.
Zurück zum Zitat Zhang Y, Li X. Relationship of serum trace elements to lung cancer. Trace Elem Health Res. 2000;17(3):15–7. Zhang Y, Li X. Relationship of serum trace elements to lung cancer. Trace Elem Health Res. 2000;17(3):15–7.
45.
Zurück zum Zitat Hu ZH, Ren Q, Guo J, et al. Significance of determination of serum zinc, copper and copper/zinc ratio on evaluating diagnosis therapeutic effect and prognosis of lung cancer. Trace Elem Sci Guangdong. 2000;7(1):19–22. Hu ZH, Ren Q, Guo J, et al. Significance of determination of serum zinc, copper and copper/zinc ratio on evaluating diagnosis therapeutic effect and prognosis of lung cancer. Trace Elem Sci Guangdong. 2000;7(1):19–22.
46.
Zurück zum Zitat Guo XH, Li PF, Peng FK, et al. Relationship between serum zinc, copper, manganese and lung cancer. Chin Pub Heal. 1994;10(4):156–7. Guo XH, Li PF, Peng FK, et al. Relationship between serum zinc, copper, manganese and lung cancer. Chin Pub Heal. 1994;10(4):156–7.
47.
Zurück zum Zitat Han CZ, Zhao XW, Jing JX, et al. [Evaluation of the serum copper zinc levels and copper/zinc ratio in the diagnosis of malignant tumor]. Chinese Tumor. 1999;8(12):572-73. Han CZ, Zhao XW, Jing JX, et al. [Evaluation of the serum copper zinc levels and copper/zinc ratio in the diagnosis of malignant tumor]. Chinese Tumor. 1999;8(12):572-73.
48.
Zurück zum Zitat Chen HF, Wu LX, Li XF, et al. A meta-analysis of association between serum iron levels and lung cancer risk. Cell Mol Biol (Noisy-le-grand). 2018;64(13):33–7.CrossRef Chen HF, Wu LX, Li XF, et al. A meta-analysis of association between serum iron levels and lung cancer risk. Cell Mol Biol (Noisy-le-grand). 2018;64(13):33–7.CrossRef
52.
Zurück zum Zitat Gómez NN, Biaggio VS, Ciminari ME, et al. Zinc: What is your role in lung cancer? Nutr Defic. 2016;Chapter 3:47–53. Gómez NN, Biaggio VS, Ciminari ME, et al. Zinc: What is your role in lung cancer? Nutr Defic. 2016;Chapter 3:47–53.
53.
Zurück zum Zitat Xie Y, Wang J, Zhao X, et al. Higher serum zinc levels may reduce the risk of cervical cancer in Asian women: a meta-analysis. J Int Med Res. 2018;46(12):4898–906.PubMedPubMedCentralCrossRef Xie Y, Wang J, Zhao X, et al. Higher serum zinc levels may reduce the risk of cervical cancer in Asian women: a meta-analysis. J Int Med Res. 2018;46(12):4898–906.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Mao S, Huang S. Zinc and copper levels in bladder cancer: a systematic review and meta-analysis. Biol Trace Elem Res. 2013;153(1-3):5–10.PubMedCrossRef Mao S, Huang S. Zinc and copper levels in bladder cancer: a systematic review and meta-analysis. Biol Trace Elem Res. 2013;153(1-3):5–10.PubMedCrossRef
55.
Zurück zum Zitat Zhao J, Wu Q, Hu X, et al. Comparative study of serum zinc concentrations in benign and malignant prostate disease: a systematic review and meta-analysis. Sci Rep. 2016;6:25778.PubMedPubMedCentralCrossRef Zhao J, Wu Q, Hu X, et al. Comparative study of serum zinc concentrations in benign and malignant prostate disease: a systematic review and meta-analysis. Sci Rep. 2016;6:25778.PubMedPubMedCentralCrossRef
Metadaten
Titel
Association between serum zinc levels and lung cancer: a meta-analysis of observational studies
verfasst von
Ying Wang
Zhengyi Sun
Aipeng Li
Yongsheng Zhang
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2019
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1617-5

Weitere Artikel der Ausgabe 1/2019

World Journal of Surgical Oncology 1/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.